Electron-Pumping Photosensitizer and Nanozyme Team Up to Kill Breast Cancer Cells Three Ways at Once

Triple-negative breast cancer remains one of the most stubborn foes in oncology. Lacking the three receptors that anchor most targeted therapies, it grows aggressively and shrugs off treatments that aim at a single vulnerability. A new study published in Materials Today Bio describes an ingeniously engineered nanoplatform that attacks the disease on several fronts simultaneously, forcing tumor cells into three distinct modes of death at once and, in doing so, waking up an immune system that the cancer had deliberately lulled to sleep.

The core problem the researchers set out to solve is a biological shell game. When therapy pushes cancer cells toward apoptosis, they respond by cranking up anti-apoptotic proteins such as Bcl-2 and Bcl-xL or by jamming the caspase cascade that executes the death signal. Switch tactics to ferroptosis, an iron-driven form of cell death fueled by lipid peroxidation, and the cells counter by boosting glutathione peroxidase 4 or importing more cystine through the System Xc− transporter, using their abundant glutathione reserves to mop up the lethal peroxides. Even pyroptosis, the inflammatory, membrane-rupturing exit, can backfire in some contexts by feeding tumor angiogenesis and immune suppression. Knock down one pathway and another pops up, a dynamic the authors liken to a game of whac-a-mole played inside an immune-evasive fortress.

Photodynamic therapy has long been proposed as a way around this compensatory maze. By flooding cells with reactive oxygen species, it inflicts broad oxidative damage that no single backup pathway can fully neutralize, and it can trigger immunogenic cell death, spilling tumor antigens and danger signals that prime immune defenses. But conventional photodynamic therapy relies on the Type II mechanism, which needs oxygen to generate singlet oxygen, and breast tumors are notoriously oxygen-starved. Worse, the treatment consumes what little oxygen remains, deepening hypoxia and potentially encouraging invasion and immune escape. Newer Type I photosensitizers, which generate radicals through electron transfer rather than energy transfer, sidestep the oxygen problem, but many of the best performers, such as Nile blue derivatives and elaborate aggregation-induced emission dyes, carry structural complexity that raises biosafety concerns.

The team’s solution is a molecular design trick they call electron pumping. They started with a classic cyanine dye scaffold, a chemistry family with a long history of FDA approval, and grafted a benzophenone moiety onto it. The cyanine backbone absorbs near-infrared light as the energy-harvesting unit, while the benzophenone group acts as the pump. Benzophenone’s carbonyl groups undergo efficient intersystem crossing through their n-π* transition, and the excited carbonyl aggressively abstracts electrons from neighboring electron-donating substrates, driving Type I photochemistry. The result, dubbed BrCy5, produced superoxide anions and hydroxyl radicals at levels 308 percent and 206 percent higher, respectively, than a control dye lacking the benzophenone pump, and it kept generating reactive oxygen even when oxygen was scarce.

Density functional theory calculations explain why the design works so well. The highest occupied molecular orbital sits on the cyanine skeleton while the lowest unoccupied orbital resides on the benzophenone group, a spatial separation that shrinks the singlet-triplet energy gap to a calculated negative value of −0.268 electronvolts between the first singlet state and the second triplet state. That negative gap means barrier-free intersystem crossing, funneling excited molecules into long-lived triplet states. The energy gap between the lowest triplet and the ground state, about 1.085 electronvolts, falls below the roughly 1.61 electronvolts needed to excite ground-state oxygen to singlet oxygen but is ample for electron transfer, which is why the molecule preferentially churns out superoxide and hydroxyl radicals through the oxygen-independent Type I route.

BrCy5 alone, however, would still face delivery problems, so the researchers packaged it inside a multifunctional nanozyme. The carrier is an iron-doped MIL-101 metal-organic framework, assembled as octahedral nanocages roughly 200 nanometers across, a size well suited to tumor accumulation through the enhanced permeability and retention effect. A hyaluronic acid shell cloaks the particle and docks onto CD44 receptors, which are abundant on breast cancer cells, granting the platform active targeting. Once inside the acidic environment of tumor cell lysosomes, the framework dissolves, releasing the dye and iron ions. At pH 7.4 the particle holds its cargo tightly, leaking only about 22 percent of the iron and 18 percent of the dye over 24 hours, but at pH 5.3 it lets go of 76 percent and 80 percent respectively, a sharp acid trigger that concentrates the payload where it is needed and spares healthy tissue.

The released iron wears two enzymatic hats. Acting like a peroxidase, it decomposes endogenous hydrogen peroxide into hydroxyl radicals, supplementing the photodynamic assault. Acting like glutathione peroxidase in reverse, it consumes glutathione, the tumor’s principal antioxidant, and downregulates GPX4, dismantling the cellular repair kit precisely when oxidative damage peaks. Meanwhile the dye accumulates in mitochondria, where light-triggered reactive oxygen devastates the organelle’s membrane potential, as shown by JC-1 staining, and drives lipid peroxidation that the crippled antioxidant system cannot contain. The mitochondrial damage also activates caspase-3, which cleaves gasdermin E into its pore-forming N-terminal fragment, tearing open the cell membrane in the explosive death known as pyroptosis. Apoptosis, ferroptosis, and pyroptosis thus fire in concert, leaving no single escape route intact.

All that orchestrated carnage pays an immunological dividend. Dying cells release damage-associated molecular patterns, including extracellular HMGB1, surface-exposed calreticulin, and secreted ATP, the canonical hallmarks of immunogenic cell death. In cell cultures the nanoplatform induced all three markers under both normal and low oxygen, and it remained selective: at 50 micrograms per milliliter in the dark, more than 80 percent of cancer cells and gastric epithelial cells survived, but after five minutes of 660-nanometer irradiation cancer cell viability collapsed to 11.9 percent in normoxia and 27.6 percent in hypoxia, while normal cells stayed above 85 percent. The team also paired the nanoplatform with sulfasalazine, a drug that blocks cystine import and starves the glutathione supply, and the combination pushed cell death to 84 percent, a further 31.1 percent reduction in GPX4 beyond what the nanoplatform achieved alone.

The decisive test came in mice bearing tumors on both flanks, allowing the researchers to treat one tumor and watch the other. In the combination group, treated with the nanoplatform, sulfasalazine, and near-infrared light, mature dendritic cells inside the primary tumor surged from 12 percent in controls to nearly 61 percent, and a similar maturation appeared in the untouched distal tumors, evidence of a systemic immune response. Immunofluorescence revealed dense infiltrates of CD3-positive, CD4-positive, and CD8-positive T cells in the untreated tumors, while immunosuppressive regulatory T cells dwindled, a classic abscopal effect. Serum levels of interferon-gamma, tumor necrosis factor-alpha, interleukin-6, and interleukin-12 all climbed, suggesting the immune system had been primed with immunological memory. Untreated control tumors ballooned from roughly 80 cubic millimeters past 830, while the combination therapy froze growth at both sites, and histology showed widespread nuclear pyknosis and tissue destruction in the treated masses.

Fluorescence imaging showed the nanoplatform accumulating in tumors within four hours of injection and clearing from major organs, reinforcing its safety profile, and the mice maintained stable body weights throughout treatment. What makes this work notable is not any single component but the architecture of the whole: a clinically grounded dye scaffold upgraded with an electron-pumping group to beat hypoxia, a smart carrier that targets, releases, and then turns the tumor’s own chemistry against it, and a drug combination that converts a cold, immune-silent tumor into an inflamed, T-cell-rich battlefield. If the paradigm translates beyond mouse models, it could offer a blueprint for treating cancers whose greatest weapon is their talent for adaptation.

Subject of Research: A multifunctional nanozyme platform combining a Type I photosensitizer and iron-based catalytic activity to induce multimodal cell death and anti-tumor immunity in triple-negative breast cancer

Article Title: Photo-induced electron pumping meets nanozyme cascade: Triggering multimodal cell death for potent triple-negative breast cancer immunotherapy

Article References: Li, Z., Xu, G., Li, F., An, Y., Dong, X., Qin, S., Guo, G., Wang, X., Yue, X., Sun, W., Song, W., & Zhong, W. (2026). Photo-induced electron pumping meets nanozyme cascade: Triggering multimodal cell death for potent triple-negative breast cancer immunotherapy. Materials Today Bio, 41, Article 103672. https://doi.org/10.1016/j.mtbio.2026.103672

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103672

Keywords: triple-negative breast cancer, photodynamic therapy, nanozyme, photosensitizer, ferroptosis, pyroptosis, immunogenic cell death, reactive oxygen species, hypoxia, metal-organic framework, tumor microenvironment, immunotherapy